Acquisition Announced

BioMarin Pharmaceutical acquisition of Alesta Therapeutics

US$275m consideration

Announced 18 Aug 2026

Advisers

Alesta Therapeutics

Target

Financial adviser
Legal adviser

BioMarin Pharmaceutical

Acquirer

Financial adviser
Legal adviser
Target
Alesta Therapeutics
Acquirer
BioMarin Pharmaceutical
Buyer based in
United States
Sector
Biotech
Tags
Biotech, Rare Disease, Drug Development

In the league tables

Similar deals

All biotech deals →

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.